Table Of Contents

1. Market Context & Strategic Relevance

 1.1 Opening Context (Why the market matters)

 1.1.1 Why This Market Is Gaining Strategic Attention

     1.1.2 Business Decisions This Report Supports

 1.2 Scope
 1.3 Research & Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size by Product

  2.3.2 Market Size by Service

  2.3.3 Market Size by Application

 2.3.4 Market Size by End Use

 2.4 Market Share & Bps Analysis by Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

    3.4.1 Genetic Testing Reagents, Assay Kits & Laboratory Consumable Suppliers

    3.4.2 Next-Generation Sequencing, PCR & Molecular Diagnostic Equipment Manufacturers

    3.4.3 BRCA1/BRCA2 Mutation & Homologous Recombination Deficiency (HRD) Assay Developers

    3.4.4 End-User

 3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting

4.1 Biomarker Prevalence & Testing Coverage Metrics

4.1.1 BRCA1/BRCA2 pathogenic variant detection rate (%) across ovarian, breast, prostate, and pancreatic cancer testing populations.

4.1.2 Homologous recombination deficiency (HRD)-positive rate (%) across eligible cancer populations, segmented by tumor type and disease stage.

4.1.3 Germline versus somatic biomarker distribution (%) across patients undergoing PARP inhibitor eligibility testing.

4.2 Diagnostic Assay Performance & Laboratory Metrics

4.2.1 Concordance rate (%) between germline testing, tumor-based genomic profiling, and HRD assay results where comparable assessments are available.

4.2.2 Biomarker testing failure rate (%) associated with insufficient tumor tissue, inadequate DNA quality, low tumor content, and sequencing limitations.

4.2.3 Average diagnostic turnaround time (days) across next-generation sequencing, PCR-based testing, and genomic instability assays.

4.3 Clinical Utility & Treatment Selection Metrics

4.3.1 PARP inhibitor treatment eligibility rate (%) among tested patients across approved biomarker-defined cancer indications.

4.3.2 Treatment initiation rate (%) among biomarker-positive patients eligible for PARP inhibitor therapy across cancer types and clinical settings.

4.3.3 Progression-free survival (months) and objective response rate (%) stratified by BRCA mutation status, HRD status, and other validated predictive biomarkers.

4.4 Companion Diagnostics & Emerging Biomarker Metrics

4.4.1 Companion diagnostic utilization (%) across tissue-based sequencing, germline genetic testing, and HRD profiling platforms.

4.4.2 Biomarker testing adoption (%) across comprehensive genomic profiling panels and specialized BRCA1/BRCA2 and HRD assays.

4.4.3 Emerging biomarker research share (%) across functional HRD assays, RAD51-based testing, genomic instability signatures, and non-BRCA DNA repair alterations.

5. PARP Inhibitor Biomarkers Market Segmental Analysis & Forecast, By Product, 2022–2035, Value (USD Billion)

    5.1 Introduction

 5.2 Kits

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Assays

6. PARP Inhibitor Biomarkers Market Segmental Analysis & Forecast, By Service, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 BRCA1/2 Testing

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 HRD Testing

 6.4 HRR Testing

 6.5 Others

7. PARP Inhibitor Biomarkers Market Segmental Analysis & Forecast, By Application, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 Breast Cancer

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Ovarian Cancer

 7.4 Prostate Cancer

 7.5 Others

8. PARP Inhibitor Biomarkers Market Segmental Analysis & Forecast, By End Use, 2022–2035, Value (USD Billion)

    8.1 Introduction

 8.2 Hospitals and Clinics

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 Diagnostic Laboratories

 8.4 Academic and Research Institutes

 8.5 Others

9. PARP Inhibitor Biomarkers Market Segmental Analysis & Forecast, By Region, 2022–2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 PARP Inhibitor Biomarkers Market Size & Forecast, By Product, 2022–2035

 9.2.3 PARP Inhibitor Biomarkers Market Size & Forecast, By Service, 2022–2035

 9.2.4 PARP Inhibitor Biomarkers Market Size & Forecast, By Application, 2022–2035

 9.2.5 PARP Inhibitor Biomarkers Market Size & Forecast, By End Use, 2022–2035

 9.2.6 PARP Inhibitor Biomarkers Market Size & Forecast, By Country, 2022–2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 PARP Inhibitor Biomarkers Market Size & Forecast, By Product, 2022–2035

 9.3.3 PARP Inhibitor Biomarkers Market Size & Forecast, By Service, 2022–2035

 9.3.4 PARP Inhibitor Biomarkers Market Size & Forecast, By Application, 2022–2035

 9.3.5 PARP Inhibitor Biomarkers Market Size & Forecast, By End Use, 2022–2035

 9.3.6 PARP Inhibitor Biomarkers Market Size & Forecast, By Country, 2022–2035

  9.3.6.1 Germany

  9.3.6.2 UK

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 PARP Inhibitor Biomarkers Market Size & Forecast, By Product, 2022–2035

 9.4.3 PARP Inhibitor Biomarkers Market Size & Forecast, By Service, 2022–2035

 9.4.4 PARP Inhibitor Biomarkers Market Size & Forecast, By Application, 2022–2035

 9.4.5 PARP Inhibitor Biomarkers Market Size & Forecast, By End Use, 2022–2035

 9.4.6 PARP Inhibitor Biomarkers Market Size & Forecast, By Country, 2022–2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 PARP Inhibitor Biomarkers Market Size & Forecast, By Product, 2022–2035

 9.5.3 PARP Inhibitor Biomarkers Market Size & Forecast, By Service, 2022–2035

 9.5.4 PARP Inhibitor Biomarkers Market Size & Forecast, By Application, 2022–2035

 9.5.5 PARP Inhibitor Biomarkers Market Size & Forecast, By End Use, 2022–2035

 9.5.6 PARP Inhibitor Biomarkers Market Size & Forecast, By Country, 2022–2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 PARP Inhibitor Biomarkers Market Size & Forecast, By Product, 2022–2035

 9.6.3 PARP Inhibitor Biomarkers Market Size & Forecast, By Service, 2022–2035

 9.6.4 PARP Inhibitor Biomarkers Market Size & Forecast, By Application, 2022–2035

 9.6.5 PARP Inhibitor Biomarkers Market Size & Forecast, By End Use, 2022–2035

 9.6.6 PARP Inhibitor Biomarkers Market Size & Forecast, By Country, 2022–2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 South Africa

  9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2025

  10.2.2 Year-Wise Strategies & Development, 2022–2025

  10.2.3 Number Of Strategies Adopted By Key Players, 2025

 10.3 Market Share Analysis, 2025

 10.4 Product/Service & Application Benchmarking

  10.4.1 Product/Service Specifications & Features By Key Players

  10.4.2 Product/Service Heatmap By Key Players

  10.4.3 Application Heatmap By Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 Myriad Genetics, Inc.

10.6.1.1 Company Overview & Snapshot

10.6.1.2 Product/Service Portfolio

10.6.1.3 Key Company Financials

10.6.1.4 SWOT Analysis

10.6.2 Illumina, Inc.

10.6.3 Thermo Fisher Scientific, Inc.

10.6.4 Foundation Medicine, Inc.

10.6.5 QIAGEN N.V.

10.6.6 Guardant Health, Inc.

10.6.7 Agilent Technologies, Inc.

10.6.8 F. Hoffmann-La Roche AG

10.6.9 Pillar Biosciences, Inc.

10.6.10 NeoGenomics Laboratories, Inc.

10.6.11 Ambry Genetics

10.6.12 CENTOGENE N.V.

10.6.13 Amoy Diagnostics Co., Ltd.

10.6.14 Invitae Corporation

10.6.15 Bio-Rad Laboratories, Inc.

10.6.16 Siemens Healthineers AG

10.6.17 AstraZeneca PLC

10.6.18 GSK plc

10.6.19 Pfizer Inc.

10.6.20 Merck & Co., Inc.

11. Analyst Recommendations

11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List Of Tables

 14.2 List Of Figures